文献速递生殖医学

IVF实验室自动化:精子准备、取卵与脱颗粒、ICSI及玻璃化——概念验证研究

Automation of sperm preparation, oocyte retrieval and denudation, ICSI, and vitrification in IVF: insights from a proof-of-concept study.
PubMed 文献 · Hum Reprod · 2026-10-26

各自动化系统均显示可行性,但样本量小、非完全自主,自动化ICSI受精率低于手动(59.6% vs 80%),并出现两例极早产导致新生儿死亡。

要点

  • 自动化精子准备、取卵脱颗粒、ICSI和玻璃化在少量病例中技术可行。
  • 自动化ICSI受精率59.6%(34/57),低于 sibling 手动ICSI的80%(36/45)。
  • 35例单胚胎移植获16例临床妊娠和16例活产,但两例极早产致新生儿死亡。

核心结论

  • 个体自动化系统用于精子准备、取卵与脱颗粒、ICSI及囊胚玻璃化在概念验证研究中显示可行性。

研究设计与样本

  • 一例因卵巢反应差被排除;卵母细胞前瞻性分配至单一自动化系统, sibling 卵母细胞按标准手动处理。

主要发现

  • Pearl 1-SU和Pearl 1-HSO自动化精子准备受精率分别为90%(18/20)和73%(27/37),手动组分别为60%(6/10)和75%(18/24)。
  • Pearl 2自动化取卵脱颗粒受精率79.4%(27/34),可移植囊胚率48.1%(13/27);手动组分别为66.7%(26/39)和76.9%(20/26)。
  • Pearl 3自动化ICSI受精率59.6%(34/57),手动组80%(36/45);可移植囊胚率自动化58.8%(20/34),手动61.1%(22/36)。
  • 35例单胚胎移植获16例临床妊娠和16例活产(26名患者);Pearl 1组两例极早产分别与严重子痫前期和阴道/尿路感染相关,导致新生儿和婴儿死亡。

临床怎么用

  • 自动化系统可作为实验性独立工具逐步整合进IVF实验室,模块化评估各环节。
  • 需密切监测自动化操作后的所有妊娠和出生结局,并收集技术与生物学数据。

局限性

  • 样本量小、pilot设计,无法对自动化与手动 sibling 卵母细胞进行统计学比较。
  • 自动化系统未实现完全自主,多项任务需操作者直接干预或数字控制执行。
  • Pearl 5存在技术限制,需进一步开发后才能进行更多临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can key embryological procedures, including sperm preparation, oocyte retrieval and denudation, ICSI, and blastocyst vitrification, be automated? SUMMARY ANSWER: Individual automated systems enabling sperm preparation, oocyte retrieval and denudation, ICSI, and embryo vitrification demonstrated feasibility in a small proof-of-concept study. WHAT IS KNOWN ALREADY: Automated systems for specific IVF procedures have shown promise, with recent reports of successful births following automated gamete isolation and ICSI. STUDY DESIGN, SIZE, DURATION: Prospective proof-of-concept study evaluating five automated systems nicknamed 'Pearls'. Each system automated one of the following procedures: sperm preparation via swim-up (Pearl 1-SU); sperm preparation by a dish-based approach called horizontal swim-out (Pearl 1-HSO), oocyte retrieval, and denudation (Pearl 2); sperm selection and laser immobilization and piezo-ICSI (Pearl 3); and blastocyst vitrification (Pearl 5). The study enrolled patients undergoing treatment at Hope IVF, Guadalajara, Mexico, between October 2023 and October 2024, with data collection on pregnancy outcomes being completed in October 2025. PARTICIPANTS/MATERIALS, SETTING, METHODS: Thirty-two patients or oocyte donors each underwent a single egg retrieval following minimal or mild ovarian stimulation. One patient was excluded from the study due to poor ovarian response. Oocytes were prospectively allocated to treatment with a single automated system: Pearl 1-SU (n = 20), Pearl 1-HSO (n = 37), Pearl 2 (n = 34), Pearl 3 (n = 57), with sibling oocytes treated manually per standard protocol. In the case of the automated vitrification system (Pearl 5), sibling blastocysts produced following manual ICSI were assigned to either manual or automated (n = 10) vitrification. MAIN RESULTS AND THE ROLE OF CHANCE: Pearl 1-SU and Pearl 1-HSO automated sperm preparation systems achieved fertilization rates of 90% (18/20) and 73% (27/37), and sibling oocytes injected with manually prepared sperm achieved 60% (6/10) and 75% (18/24) fertilization. Usable blastocyst rates were 55.5% (10/18) and 70.4% (19/27) for the automated systems, and 50% (3/6) and 66.7% (12/18) for manual preparation. Pearl 2 automated oocyte retrieval and denudation resulted in a fertilization rate of 79.4% (27/34) and a usable blastocyst rate of 48.1% (13/27); manual procedures achieved 66.7% (26/39) and 76.9% (20/26) fertilization and blastocyst formation rates, respectively. Pearl 3 automated ICSI resulted in a fertilization rate of 59.6% (34/57), while this rate in sibling oocytes injected manually was 80% (36/45). Usable blastocyst formation rates were 58.8% (20/34) for automated and 61.1% (22/36) for manual ICSI. Thirty-five single embryo transfers from the automation group resulted in 16 clinical pregnancies and 16 live births in 26 patients (Pearl 1-SU = 3/6; Pearl 1-HSO = 4/7; Pearl 2 = 4/7; Pearl 3 = 4/13; Pearl 5 = 1/2). Two extremely preterm deliveries in the Pearl 1 group, associated with severe pre-eclampsia and vaginal/urinary infection, respectively, led to neonatal and infant deaths. No transfers involved embryos from the manual group for Pearl 1. One embryo transfer from the manual group of Pearl 2 resulted in a negative pregnancy. In the Pearl 3 manual group, four single blastocyst transfers in four patients resulted in four live births; in the Pearl 5 manual control group, three transfers in three patients resulted in two negative pregnancy results and one early pregnancy loss. LIMITATIONS, REASONS FOR CAUTION: The small sample size and pilot design of this study do not allow statistical comparisons between sibling oocytes from automated and manual treatment groups. The automated systems did not achieve complete autonomy, and several tasks required direct operator intervention or execution through digital control. Pearl 5 encountered technical limitations that require further development before additional clinical evaluation. Although the two extremely preterm births that led to neonatal and infant deaths occurred in the context of clear obstetric complications, they compel collection and analysis of extensive technical and biological data from the automated systems in future studies and close monitoring of all pregnancies and births resulting from these novel procedures. WIDER IMPLICATIONS OF THE FINDINGS: These results show the feasibility of integrating individual automated systems into an IVF laboratory as experimental standalone tools, allowing a stepwise evaluation. The modular approach, once shown to be efficacious, may provide a practical pathway toward broader laboratory automation and enable laboratories to address specific bottlenecks and standardize operations. FUNDING: The study was sponsored by Conceivable Life Sciences, New York, NY, USA. DISCLOSURES: A.C.-B. is an employee, shareholder, and company officer at Conceivable Life Sciences and a shareholder in IVF 2.0 and Hope IVF Mexico. A.V.A. has no conflicts of interest to declare. G.M.-R. is a stock option holder in Conceivable Life Sciences and has received consulting fees from Conceivable Life Sciences and IVF 2.0. A.F.-S.F. is an employee and stock option holder at Conceivable Life Sciences. E.H.-M. is an employee and stock option holder at Conceivable Life Sciences. A.Á.L. is an employee and stock option holder at Conceivable Life Sciences. D.J.S.-G. has no conflicts of interest to declare. N.C.-B. is a stock option holder in Conceivable Life Sciences and has received consulting fees from the company; he is also an employee, shareholder, and company officer at Embryotools. A.M. is a shareholder and company officer at Conceivable Life Sciences and holds shares in TMRW Life Sciences. M.A. is a stock option holder at Conceivable Life Sciences and has received consulting fees and travel support from the company; she has also received consulting fees from TMRW Life Sciences. G.S. is an employee and stock option holder at Conceivable Life Sciences. J.C. is an employee, shareholder, stock option holder, and company officer at Conceivable Life Sciences. Furthermore, several authors declare inventorship on multiple US patents and pending applications relating to IVF automation technology: 12,349,940 B2 (automated oocyte denudation; A.C.-B., G.M.-R., A.F.-S.F., A.Á.L., A.M., J.C.), 12,245,793 B2 (robotic handling systems; A.C.-B., G.M.-R., A.F.-S.F., E.H.-M., A.M., J.C.), 12,178,475 B1 (automated sperm preparation; A.C.-B., G.M.-R., A.F.-S.F., A.M., G.S., J.C.), 12,180,441 B1 (laboratory workflow automation; A.C.-B., G.M.-R., A.M., J.C.), 12,268,418 B2 (automated oocyte preparation; A.C.-B., G.M.-R., A.F.-S.F., A.Á.L., N.C.-B., A.M., J.C.), 12,310,625 B2 (automated ICSI; A.C.-B., G.M.-R., A.F.-S.F., E.H.-M., N.C.-B., A.M., J.C.), 12,253,516 B2 (optical systems for IVF automation; A.C.-B., G.M.-R., A.F.-S.F., A.M.), 12,226,125 B2 (automated vitrification; A.C.-B., G.M.-R., A.F.-S.F., N.C.-B., A.M., G.S., J.C.), and 12,478,405 B2 (automated dish-based sperm preparation; A.C.-B., G.M.-R., N.C.-B., J.C.). Pending applications cover automated dish preparation technology (A.C.-B., G.M.-R., N.C.-B., M.A., A.M., J.C.), automated oocyte denudation (A.C.-B., G.M.-R., N.C.-B., J.C.), automated vitrification systems (A.C.-B., E.H.-M., N.C.-B., A.M., J.C.), and cumulus-oocyte complex detection technology (A.C.-B., G.M.-R., J.C.). TRIAL REGISTRATION NUMBER: NCT06074835 (ClinicalTrials.gov, 4 October 2023).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Chavez-Badiola A, Valadez Aguilar A, Mendizabal-Ruiz G, et al. Automation of sperm preparation, oocyte retrieval and denudation, ICSI, and vitrification in IVF: insights from a proof-of-concept study. Hum Reprod. 2026. PMID: 42932986. doi:10.1093/humrep/deag168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。